RARα-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia Journal Article


Authors: Guidez, F.; Parks, S.; Wong, H.; Jovanovic, J. V.; Mays, A.; Gilkes, A. F.; Mills, K. I.; Guillemin, M. C.; Hobbs, R. M.; Pandolfi, P. P.; De Thé, H.; Solomon, E.; Grimwade, D.
Article Title: RARα-PLZF overcomes PLZF-mediated repression of CRABPI, contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia
Abstract: Leukemia-associated chimeric oncoproteins often act as transcriptional repressors, targeting promoters of master genes involved in hematopoiesis. We show that CRABPI (encoding cellular retinoic acid binding protein I) is a target of PLZF, which is fused to RARα by the t(11;17)(q23;q21) translocation associated with retinoic acid (RA)-resistant acute promyelocytic leukemia (APL). PLZF represses the CRABPI locus through propagation of chromatin condensation from a remote intronic binding element culminating in silencing of the promoter. Although the canonical, PLZF-RARα oncoprotein has no impact on PLZF-mediated repression, the reciprocal translocation product RARα-PLZF binds to this remote binding site, recruiting p300, inducing promoter hypomethylation and CRABPI gene up-regulation. In line with these observations, RA-resistant murine PLZF/RARα+RARα/PLZF APL blasts express much higher levels of CRABPI than standard RA-sensitive PML/RARα APL. RARα-PLZF confers RA resistance to a retinoid-sensitive acute myeloid leukemia (AML) cell line in a CRABPI-dependent fashion. This study supports an active role for PLZF and RARα-PLZF in leukemogenesis, identifies up-regulation of CRABPI as a mechanism contributing to retinoid resistance, and reveals the ability of the reciprocal fusion gene products to mediate distinct epigenetic effects contributing to the leukemic phenotype. © 2007 by The National Academy of Sciences of the USA.
Keywords: controlled study; unclassified drug; oncoprotein; gene translocation; human cell; promoter region; genetics; disease course; nonhuman; molecular genetics; protein analysis; animal cell; metabolism; protein targeting; cell line; protein binding; gene locus; drug effect; drug resistance; pathology; drug resistance, neoplasm; dna methylation; gene expression regulation; leukemia, promyelocytic, acute; gene expression regulation, neoplastic; molecular sequence data; chromatin; disease progression; nucleotide sequence; gene repression; tumor protein; promyelocytic leukemia; kruppel like factor; kruppel-like transcription factors; murinae; base sequence; binding site; gene control; binding sites; upregulation; gene silencing; up-regulation; chromosome 11; chromosomes, human, pair 11; retinoic acid; retinoid; chromosome 17; chromosomes, human, pair 17; retinoic acid receptor alpha; retinoic acid receptor; retinoids; protein p300; chromatin condensation; receptors, retinoic acid; remodelling; protein crabp1; protein raralpha plzf; retinoic acid binding protein i, cellular; zbtb16 protein, human
Journal Title: Proceedings of the National Academy of Sciences of the United States of America
Volume: 104
Issue: 47
ISSN: 0027-8424
Publisher: National Academy of Sciences  
Date Published: 2007-11-20
Start Page: 18694
End Page: 18699
Language: English
DOI: 10.1073/pnas.0704433104
PUBMED: 18000064
PROVIDER: scopus
PMCID: PMC2141839
DOI/URL:
Notes: --- - "Cited By (since 1996): 11" - "Export Date: 17 November 2011" - "CODEN: PNASA" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robin Mark Hobbs
    21 Hobbs